Note from the Editors on Recent Developments
We are pleased to announce an important new initiative at RNA. We will be launching a new regular section dedicated to RNA therapeutics. For this, we are pleased to report that Michelle Hastings (University of Michigan) has agreed to serve as Editor for this new section, as RNA Therapeutics Editor. Please see the information below. You will be hearing directly from Michelle, with more details about the new RNA Therapeutics section, when it begins in the very near future.
We have also reorganized the format of the journal, which will now have papers in five categories: Communications (Letters to the Editor, Hypotheses, and Perspectives); Reviews; RNA and Gene Expression; RNA Therapeutics; and Bioinformatics and Databases.
Within the category Communications, Letters to the Editor are intended as a forum for raising or clarifying issues of specific interest to the RNA community. Hypotheses outline novel concepts or new ways of integrating existing data. Perspectives outline a novel way of looking at existing literature. As for all our published papers, manuscripts within this category are subject to peer review.
Manuscripts in the categories RNA and Gene Expression, RNA Therapeutics, and Bioinformatics and Databases can be in the format of Articles, Reports, or Methods. Each of these formats is described on our website at https://rnajournal.cshlp.org/site/misc/about.xhtml.
Manuscripts in the category Reviews are usually by invitation, but pre-submission inquiries to the Reviews Editor, Tom Cech (HHMI, University of Colorado, Boulder), are welcome. We will continue to publish timely Special Issues, led by Special Reviews Editor Tim Nilsen.
We look forward to hearing from you and working with you and are happy to discuss other ways RNA can help you disseminate your research.
Eric M. Phizicky, Senior Editor, RNA and Javier F. Caceres, Senior Editor, RNA
Michelle L. Hastings, PhD, is the Pfizer Upjohn Research Professor of Pharmacology at the University of Michigan Medical School, Professor of Medicinal Chemistry in the College of Pharmacy and Director of the M-RNA Therapeutics Initiative in the Center for RNA Biomedicine. Dr. Hastings received her PhD from Marquette University, trained as a postdoctoral fellow at Cold Spring Harbor Laboratory, and was Professor and Director of the Center for Genetic Diseases at the Chicago Medical School, Rosalind Franklin University of Medicine and Science before joining the University of Michigan in 2023. Research in her lab focuses on understanding the genetic and molecular basis of disease and discovering therapeutics based on targeting or utilizing RNA. Work in her lab has resulted in the discovery of new treatment approaches for diseases such as cystic fibrosis, Usher syndrome, Alzheimer's, Parkinson's, Batten disease, and other pathological conditions. Dr. Hastings is a member of numerous editorial and scientific advisory boards and committed to the advancement of science through her work with scientific societies. She is passionate about education and training and dedicated to increasing diversity in the STEM fields. Dr. Hastings has been a part of the RNA Society community for more than 25 years and is delighted to serve the RNA journal in her new capacity as RNA Therapeutics Section Editor.
